ASISA Partners with HCLTech to Drive Digital Transformation and Expansion in Iberia
HCLTech, a leading global technology company, has been selected by ASISA, a prominent health insurance provider in Spain, as its strategic IT partner to accelerate business transformation and expansion in Iberia. This partnership aims to accelerate ASISA's digital transformation journey to enhance the experience for its 2.2 million customers and position the company at the forefront of innovation in the region.
HCLTech will modernize ASISA's IT platforms and leverage AI-based solutions to enhance business efficiency. The comprehensive mainframe modernization and solutions from HCLTech will enable ASISA to create a more agile, responsive IT infrastructure.
“Partnering with HCLTech marks a key step in our digital transformation journey. By modernizing our platforms and embracing cutting-edge technologies, we are reinforcing our commitment to delivering exceptional service to our customers,” said José Pereira, CTO at ASISA. “This collaboration will empower ASISA with a more agile, scalable and efficient infrastructure—driving innovation and preparing us for the future”.
"We are proud to partner with ASISA on this transformative journey," said Sudip Lahiri, Executive Vice President and Head of Financial Services for Europe at HCLTech. "This deal highlights our commitment to investing in Iberia and delivering cutting-edge solutions that drive business success. Our extensive mainframe and infrastructure services will enable ASISA to achieve its strategic goals and set new benchmarks in the Iberian region."
View source version on businesswire.com: https://www.businesswire.com/news/home/20250617387118/en/
Contacts
For more information, please contact:
Meredith Bucaro, Americas
meredith-bucaro@hcltech.com
Elka Ghudial, EMEA
elka.ghudial@hcltech.com
James Galvin, APAC
james.galvin@hcltech.com
Nitin Shukla, India
nitin-shukla@hcltech.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Jerrod Chong, Yubico ’ s Chief Operating Officer, appointed as acting CEO17.12.2025 08:05:00 CET | Press Release
Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and the leading provider of hardware authentication security keys, today announced that Jerrod Chong, Yubico’s current Chief Operating Officer, has been appointed to serve as acting CEO. Mattias Danielsson will be stepping down from his role as CEO of Yubico. "I am very pleased that Jerrod has accepted the role of acting CEO. With his extensive experience in cybersecurity and twelve years in senior leadership at Yubico, I am confident that he will lead Yubico on a continued path of growth and he will ensure Yubico maintains and strengthens its leading position. On behalf of the board, I also want to extend our sincere thanks to Mattias Danielsson for his hard work and significant contributions to Yubico’s development as a respected leader and colleague over sixteen years. We deeply appreciate his commitment to Yubico over the years," says Patrik Tigerschiöld, Chairman of the Board. "Yubico is entering an excitin
VeritasChain Unveils VAP Architecture, New Auditability Research, and Confirms Submissions to 58 Regulators Globally17.12.2025 08:00:00 CET | Press Release
VeritasChain today unveiled its Verifiable AI Provenance Framework (VAP) architecture, published new research on verifiable audit trails, and confirmed informational submissions to 58 regulatory authorities across 43 jurisdictions. These milestones advance VeritasChain’s mission to establish a global framework for verifiable auditability in AI and algorithmic trading. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251216433807/en/ Map indicates jurisdictions where regulatory outreach or informational submissions have been made as of Dec 2025. Verifiable AI Provenance Framework (VAP) VAP is a layered assurance architecture designed for independent verification of AI decision-making. It is not a single product, but a framework defining how cryptographic evidence and third-party verification interoperate across diverse systems. The architecture records decision-to-execution events as immutable audit trails, facilitating regulat
Outpost24 Secures New Investment to Scale its Exposure Management and Identity Security Solutions17.12.2025 08:00:00 CET | Press Release
Outpost24, a leader in exposure management and identity security, today announced a new investment from Vitruvian Partners to fuel its next phase of global growth. This significant new funding will accelerate innovation across the company's platform, with a focus on integrating AI capabilities to optimize how security teams identify and neutralize critical vulnerabilities. The only European vendor recognized as an overall leader in the 2025 KuppingerCole Leadership Compass Report for Attack Surface Management, Outpost24 delivers a distinct approach to cyber defence that empowers security teams to gain a complete understanding of their digital and human risk landscape. Last week, Outpost24 announced the acquisition of Infinipoint, a specialist in device identity, posture validation, and secure workforce access. The acquisition marks the company's entry into the Zero Trust Workforce Access market and lays the foundation for its identity security division, Specops, to offer a unified appr
New Published Data Confirms Nemluvio ® (Nemolizumab) Can Rapidly Relieve Itch and Improve Sleep in as Early as Two Days in Both Atopic Dermatitis and Prurigo Nodularis17.12.2025 07:00:00 CET | Press Release
Galderma (SIX: GALD), the pure-play dermatology category leader, today released new clinical data confirming nemolizumab’s rapid onset of action on itch and sleep, with significant improvements observed as early as 48 hours after treatment in some patients with atopic dermatitis and prurigo nodularis.1 The findings from post-hoc analyses of the phase III ARCADIA and OLYMPIA clinical trial programs were published in the Journal of the European Academy of Dermatology and Venereology. Nemolizumab is the first approved monoclonal antibody that specifically targets IL-31 receptor alpha, inhibiting the signalling of IL-31.2,5,6 IL-31 is a neuroimmune cytokine that drives itch and other symptoms in both atopic dermatitis and prurigo nodularis.3,4 These new findings reinforce the critical role of IL-31 pathway inhibition in achieving rapid itch response. Atopic dermatitis and prurigo nodularis are debilitating skin conditions that significantly affect quality of life, with symptoms such as per
Mori Memorial Foundation’s Global Power City Index 2025 Sees City Rankings Shift Due to Tourism Gains in East Asia and Inflationary Pressures in the West17.12.2025 04:00:00 CET | Press Release
The Mori Memorial Foundation’s Institute for Urban Strategies, a research body established by Mori Building, Tokyo’s leading urban landscape developer, today published its annual Global Power City Index (GPCI) 2025, a report evaluating the urban competitiveness of 48 major cities worldwide. The report also includes the GPCI–Financial Centers index, an assessment of cities as international financial centers, and the new GPCI–Startup Ecosystems index, which assesses the competitiveness of startup environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251216187692/en/ 48 Major Cities Evaluated in Mori Memorial Foundation’s GPCI-2025 Report This year’s report highlights the remarkable rise of East Asian cities and the stagnation of several Western cities, showing how global challenges, such as geopolitical tensions and regional disparities in inflation, are greatly impacting the performance of major cities worldwide. The r
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom